
Elio Gregory Pizzutilo
@eliogreg
Followers
461
Following
2K
Media
49
Statuses
573
MD, Medical Oncologist @ospNiguarda #LCSM #ThoracicOncology Always find a way to have fun!
Milan, Lombardy
Joined January 2017
#ARTICUNO study finally published! @ESMO_Open .📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib.🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms .🔎 #E709 mut->lack of benefit
2
19
73
RT @JordiRemon: HARMONi: Ivonescimab+CT ⬆️ PFS vs CT in post-osi EGFRm NSCLC.Qx:.-How and when to place this strategy based new SoC 1st lin….
0
21
0
RT @JordiRemon: FLAURA2 trial: Osi + CT improves PFS & OS (⬇️ 23% risk death) vs Osi alone in mEGFR NSCLC. Qx:.-Intensification for all pt….
0
58
0
RT @GlobalSumudF: Wishing the best of luck today to everyone departing from Barcelona and Genoa, and to those setting sail on the 4th from….
0
3K
0
RT @FranceskAlbs: ❗️BREAKING❗️Rescuers killed in line of duty. Scenes like this unfold every moment in Gaza, often unseen, largely undocum….
0
31K
0
RT @FranceskAlbs: This is not business as usual. My new UN report, From Economy of Occupation to Economy of Genocide, is out today. It show….
0
13K
0
RT @avantibionda: Boicottare Israele si deve perché è l’unica cosa che noi possiamo fare per opporci al genocidio dei palestinesi. E dobbia….
0
353
0
RT @DrYukselUrun: In France’s non-academic hospitals:.🫁Lung adenocarcinoma survival more than doubled from 2000 to 2020!.One clear message:….
0
20
0
The #oncology social community is expanding rapidly on @bluesky .Let’s boycott Musk and move away from X today.#lcsm .@OncoAlert .@EGFRResisters @KRASKickers.
0
0
1
RT @lungoncdoc: #lcsm: while small numbers from this phase 2 @JTOonline study, 5-year OS data seems to support 1L lorlatinib (76%!). With t….
0
12
0
RT @dplanchard: Triple targeted therapy is effective for pts with EGFR-mutant NSCLC with acquired BRAF alterations, mainly among pts with B….
0
18
0
RT @DrJNaidoo: 🔥Press Release: Ph III IMforte trial shows PFS+OS benefit for maintenance lurbinectadin + atezo post chemo-immunotherapy for….
investor.jazzpharma.com
Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN , Oct. 15, 2024 /PRNewswire/ -- Jazz...
0
30
0
RT @FSkoulidis: Excited to share our new study @Nature. Very grateful for the support of our collaborators, pharma and biotech partners and….
0
92
0
RT @SamuelBHume: Biggest medical discoveries of the week (🧵). 1/10. A complete map of the fruit fly brain - the biggest and most detailed t….
0
168
0
RT @LeXiuning: Germline EGFR T790M occurs more often in Whites, with a distinct radiological pattern and family history of lung cancer with….
0
30
0
RT @RobertoFerrara_: Very 'out of box' overview of ICI treatment duration in NSCLC from @g_mountzios at @LungSummit.2 years versus 5 years….
0
10
0
RT @Aiims1742: New #OpenAccess perspective in @NatureRevCancer .Defining precancer: a grand challenge for the cancer community. https://t.co….
0
53
0